IGC Pharma (IGC) Intangibles (2011 - 2026)

IGC Pharma (IGC) has reported Intangibles for 16 consecutive years, with $5.5 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Intangibles rose 168.98% year-over-year to $5.5 million in Q1 2026; TTM through Mar 2026 was $5.5 million, a 168.98% increase from a year earlier, with the FY2026 full-year figure at $5.5 million, up 168.98% from the prior year.
• Intangibles was $5.5 million for Q1 2026 at IGC Pharma, up from $5.4 million in the prior quarter.
• Over five years, Intangibles peaked at $5.5 million in Q1 2026 and troughed at $917000.0 in Q1 2022.
• A 5-year average of $2.1 million and a median of $1.6 million in 2024 frame the typical range for Intangibles.
• Across the five-year window, Intangibles gained 15.66% in 2023 and jumped 186.3% in 2025, its largest moves.
• Over 5 years, Intangibles stood at $1.0 million in 2022, then grew by 15.66% to $1.2 million in 2023, then soared by 58.12% to $1.9 million in 2024, then jumped by 186.3% to $5.4 million in 2025, then increased by 3.4% to $5.5 million in 2026.
• The last three Intangibles figures came in at $5.5 million (Q1 2026), $5.4 million (Q4 2025), and $5.1 million (Q3 2025), per Business Quant data.